RxDoctor Payments Data

Sreedhar Gottiparthy, MD

Internal Medicine · Cypress, TXNPI 1659454940

Payments from drug & device makers

$18,363in general payments, 2019–2025

Across 943 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$2K
  • GSK$2K
  • Boehringer Ingelheim$2K
  • AbbVie$1K
  • Merck$1K
  • plus $8K from 41 others

What the payments were for

  • Food & beverage$18,06198%
  • Education$3022%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,363 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$60,880
Medicare patients
143
Services billed
581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide14$27,891
TrulicityDulaglutide12$15,130
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$6,867
Rosuvastatin Calcium112$818
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav76$579
Atorvastatin Calcium65$535
Oxybutynin Chloride ErOxybutynin Chloride13$474
Valsartan12$431
Albuterol Sulfate HfaAlbuterol Sulfate14$431
Pantoprazole Sodium66$419
Olmesartan Medoxomil40$404
Levothyroxine Sodium62$400
Escitalopram Oxalate37$345
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst25$236
Losartan Potassium29$212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,687$27,89114 claims
Lilly USA, LLCTrulicity$870$15,13012 claims
Almatica Pharma LLCSertraline Hcl$37$18227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Cypress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →